Our website has a fresh new "look"
We've updated our site with modern design and easier navigation, but you'll still find the same quality Dharmacon™ reagents and Mimix™ reference standards that you love.
What is the importance of measuring PTEN loss and what is the relation of this marker with cancer progression?
PTEN loss is prevalent across various cancers, notably occurring in 15-20% of primary prostate cancer and up to 40-60% in advanced stages. It serves as a diagnostic marker in tumors like prostate, breast, lung, and colon, while also acting as a prognostic biomarker, tracking disease progression from localized to metastatic stages. Also, PTEN loss can predict drug response in some cancers.